Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Fibrolamellar Carcinoma”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Early research (Phase 1)Study completedNCT02159989
What this trial is testing

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmFibrolamellar CarcinomaMetastatic Malignant Solid Neoplasm+5 more
National Cancer Institute (NCI) 83
Testing effectiveness (Phase 2)Looking for participantsNCT04134559
What this trial is testing

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma, ChildhoodFibrolamellar CarcinomaLiver Cancer+1 more
Allison O'Neill, MD 18
Testing effectiveness (Phase 2)Temporarily pausedNCT05468359
What this trial is testing

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Who this might be right for
Refractory Solid TumorHepatocellular CarcinomaMalignant Solid Tumor+3 more
St. Jude Children's Research Hospital 64
Testing effectiveness (Phase 2)Active Not RecruitingNCT06521567
What this trial is testing

Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Who this might be right for
MelanomaHodgkin LymphomaHigh and Low Grade Glioma+9 more
GlaxoSmithKline 83
Testing effectiveness (Phase 2)Looking for participantsNCT06620302
What this trial is testing

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Who this might be right for
Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar CarcinomaRecurrent Childhood Malignant Solid Neoplasm+6 more
Children's Oncology Group 81